HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
PVLA
Palvella Therapeutics, Inc.
There isn't enough reported data to score PVLA yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
PVLA Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
PVLA's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
PVLA PE Valuation
PVLA has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
PVLA Forward outlook
There aren't enough analyst estimates for PVLA to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
PVLA has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus PVLA down 142%.
PVLA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$12.97 | +$14.97 |
| Q2 2024 | -$19.58 | +$9.96 |
| Q1 2024 | -$12.82 | +$31.92 |
| Q4 2023 | -$23.27 | +$12.67 |
| Q3 2023 | -$27.94 | +$11.26 |
| Q2 2023 | -$29.54 | +$18.46 |
| Q1 2023 | -$44.74 | +$12.06 |
| Q4 2022 | -$35.94 | +$20.86 |
PVLA is still losing money, but far less than before: $5.50 per share over the past year, against $67.20 at its worst in mid-2021.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the stronger quarterly revenue trend. Revenue is up 49% for HIMS versus down 100% for PVLA.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
PVLA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2024 | $53K | -97% |
| Q4 2023 | $1.3M | -78% |
| Q3 2023 | $19.5M | +264% |
| Q2 2023 | $20.1M | +442% |
| Q1 2023 | $1.9M | -82% |
| Q4 2022 | $5.8M | -31% |
| Q3 2022 | $5.4M | +32% |
| Q2 2022 | $3.7M | +13% |
PVLA's revenue has slid since its 2023 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2024 | -10006% | -9205 points |
| Q4 2023 | -347% | -150 points |
| Q3 2023 | -60% | +166 points |
| Q2 2023 | 10% | +344 points |
| Q1 2023 | -801% | -733 points |
| Q4 2022 | -197% | -67 points |
| Q3 2022 | -227% | +242 points |
| Q2 2022 | -333% | +177 points |
PVLA's operating margin was −10006% last quarter, down 9204 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over PVLA on cash generation, producing positive trailing cash flow while its opponent burns cash.
PVLA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$14.4M | -$6.6M |
| Q2 2026 | -$12.8M | -$7.4M |
| Q1 2026 | -$10.9M | -$4.1M |
| Q4 2025 | -$4.9M | -$2.4M |
| Q3 2025 | -$7.9M | -5496% |
| Q2 2025 | -$5.4M | -$4M |
| Q1 2025 | -$6.8M | +$228K |
| Q4 2024 | -$2.5M | +$17.1M |
PVLA has burned cash in almost every quarter: −$43M over the past year, against −$23M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over PVLA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
PVLA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +175K shares |
| 1 year | +31% | +3.5M shares |
| 3 years | +1460% | +13.6M shares |
| 5 years | +1965% | +13.8M shares |
| Available history | +2196% | +13.9M shares |
PVLA has 15M diluted shares, up 31% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
PVLA Net Leverage
PVLA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
PVLA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.2 | Neutral |
| Stochastic | 73.5 | Neutral |
PVLA's weekly RSI is 55 (neutral) and its Stochastic is 73 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
PVLA PE vs Healthcare Sector
PVLA has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
PVLA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $141.3 | 8.4% above |
| 20 week MA | $146.0 | 4.9% above |
| 50 week MA | $124.4 | 23% above |
| 100 week MA | $81.0 | 89% above |
| 200 week MA | $56.7 | 170% above |
PVLA has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
PVLA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $265.6 | $219.2 | -17% |
| 2021 | $219.2 | $293.6 | +34% |
| 2022 | $293.6 | $72.8 | -75% |
| 2023 | $72.8 | $14.6 | -80% |
| 2024 | $14.6 | $12.0 | -18% |
| 2025 | $12.0 | $103.4 | +761% |
| 2026 YTD | $103.4 | $153.2 | +48% |
PVLA has the edge over HIMS on returns for 2026, with the stronger performance.